Therefore, in this study, we performed a comprehensive analysis including m6A RNA immunoprecipitation (MeRIP) sequencing (MeRIP-seq) and site-specific methylation editing techniques to elucidate how METTL3 creates a favorable environment for pancreatic adenocarcinoma and to explore new therapeutic targets to improve the clinical outcomes in patients with pancreatic adenocarcinoma, which has a poor prognosis. The gene discussed is METTL3; the disease is pancreatic adenocarcinoma.